🇺🇸 FDA
Pipeline program

[68Ga]FAPI-46

19097

Approved small_molecule active

Quick answer

[68Ga]FAPI-46 for post-acute sequelae of COVID-19 is a Approved program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).

Program details

Company
Disc Medicine
Indication
post-acute sequelae of COVID-19
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials